Filing Details
- Accession Number:
- 0000950142-21-003503
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-02 16:04:47
- Reporting Period:
- 2021-08-16
- Accepted Time:
- 2021-11-02 16:04:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1719406 | Nrx Pharmaceuticals Inc. | NRXP | Pharmaceutical Preparations (2834) | 822844431 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1864650 | Robert Besthof | C/O Nrx Pharmaceuticals, Inc. 1201 North Market Street, Suite 111 Wilmington DE 19801 | Chief Comm. & Patient Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-16 | 63,710 | $0.20 | 63,710 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-09-15 | 40,000 | $11.76 | 23,710 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to buy) | Disposition | 2021-08-16 | 100,000 | $0.20 | 100,000 | $0.20 |
| Common Stock | Restricted Stock Units | Acquisiton | 2021-08-16 | 36,290 | $0.00 | 36,290 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 247,200 | 2026-03-01 | No | 4 | C | Direct | |
| 36,290 | No | 4 | A | Direct |
Footnotes
- The options are fully vested.
- Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.
Billionaire Hedge Funds
